The latest announcement is out from Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ).
Shanghai Henlius Biotech, Inc. announced that its anti-PD-1 monoclonal antibody, HANSIZHUANG, has received approval from the European Commission for use in combination with chemotherapy as a first-line treatment for extensive-stage small cell lung cancer in adults. This marks the company’s second product approved for marketing in the EU and the first anti-PD-1 antibody for this indication in the region. The approval is based on positive results from a Phase 3 clinical study, demonstrating significant benefits over standard chemotherapy. The announcement signifies a crucial milestone for Henlius, enhancing its competitive positioning in the oncology market, while also bolstering its strategic expansion in Europe and other global regions.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a pharmaceutical company based in China, specializing in the development of innovative monoclonal antibodies. The company focuses on oncology and has a significant market presence in the area of lung cancer treatments.
YTD Price Performance: -25.06%
Average Trading Volume: 692,435
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$9.23B
See more insights into 2696 stock on TipRanks’ Stock Analysis page.